These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27262526)

  • 1. Old dogs and new tricks in antimicrobial discovery.
    Butler MS; Blaskovich MA; Owen JG; Cooper MA
    Curr Opin Microbiol; 2016 Oct; 33():25-34. PubMed ID: 27262526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents.
    Provenzani A; Hospodar AR; Meyer AL; Leonardi Vinci D; Hwang EY; Butrus CM; Polidori P
    Int J Clin Pharm; 2020 Aug; 42(4):1016-1025. PubMed ID: 32638294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotics in the clinical pipeline in 2011.
    Butler MS; Cooper MA
    J Antibiot (Tokyo); 2011 Jun; 64(6):413-25. PubMed ID: 21587262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Will new antimicrobials overcome resistance among Gram-negatives?
    Bassetti M; Ginocchio F; Mikulska M; Taramasso L; Giacobbe DR
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):909-22. PubMed ID: 21973303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mastering the Gram-negative bacterial barrier - Chemical approaches to increase bacterial bioavailability of antibiotics.
    Ropponen HK; Richter R; Hirsch AKH; Lehr CM
    Adv Drug Deliv Rev; 2021 May; 172():339-360. PubMed ID: 33705882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of 'old antibiotics' against highly resistant Gram-negative bacteria.
    Dubourg G; Okdah L; Le Page S; Rolain JM; Raoult D
    Int J Antimicrob Agents; 2015 Dec; 46(6):718-20. PubMed ID: 26589488
    [No Abstract]   [Full Text] [Related]  

  • 7. Antibiotics in the clinical pipeline in October 2019.
    Butler MS; Paterson DL
    J Antibiot (Tokyo); 2020 Jun; 73(6):329-364. PubMed ID: 32152527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A paradigm shift in drug development for treatment of rare multidrug-resistant gram-negative pathogens.
    Alemayehu D; Quinn J; Cook J; Kunkel M; Knirsch CA
    Clin Infect Dis; 2012 Aug; 55(4):562-7. PubMed ID: 22610933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Creative targeting of the Gram-negative outer membrane in antibiotic discovery.
    MacNair CR; Tsai CN; Brown ED
    Ann N Y Acad Sci; 2020 Jan; 1459(1):69-85. PubMed ID: 31762048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic sideromycins (skepticism and optimism): selective generation of either broad or narrow spectrum Gram-negative antibiotics.
    Lin YM; Ghosh M; Miller PA; Möllmann U; Miller MJ
    Biometals; 2019 Jun; 32(3):425-451. PubMed ID: 30919118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New EMA guideline for antimicrobial development.
    Ambrose PG; Bhavnani SM; Dudley MN; Ellis-Grosse E; Rubino CM; Drusano GL
    Lancet Infect Dis; 2012 Apr; 12(4):265-6. PubMed ID: 22459079
    [No Abstract]   [Full Text] [Related]  

  • 12. What is in the pipeline for Gram-negative pathogens?
    Talbot GH
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):39-49. PubMed ID: 18251663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In memoriam: John P. Quinn, MD.
    Perez F; Arias CA; Bush K; Drusano GL; Lolans K; Munoz-Price LS; Nicolau DP; Queenan AM; Rice LB; Segreti J; Shlaes DM; Weinstein RA; Bonomo RA
    Clin Infect Dis; 2014 Mar; 58(5):748-50. PubMed ID: 24336826
    [No Abstract]   [Full Text] [Related]  

  • 14. Advances and challenges in bacterial compound accumulation assays for drug discovery.
    Six DA; Krucker T; Leeds JA
    Curr Opin Chem Biol; 2018 Jun; 44():9-15. PubMed ID: 29803973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confronting the threat of multidrug-resistant Gram-negative bacteria in critically ill patients.
    Cohen J
    J Antimicrob Chemother; 2013 Mar; 68(3):490-1. PubMed ID: 23152481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?
    Falagas ME; Mavroudis AD; Vardakas KZ
    Expert Rev Anti Infect Ther; 2016 Aug; 14(8):747-63. PubMed ID: 27400643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement.
    Chopra I; Schofield C; Everett M; O'Neill A; Miller K; Wilcox M; Frère JM; Dawson M; Czaplewski L; Urleb U; Courvalin P
    Lancet Infect Dis; 2008 Feb; 8(2):133-9. PubMed ID: 18222164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming multidrug resistance in gram-negative bacteria.
    Poole K
    Curr Opin Investig Drugs; 2003 Feb; 4(2):128-39. PubMed ID: 12669372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New aminoglycoside antibiotics.
    Dozzo P; Moser HE
    Expert Opin Ther Pat; 2010 Oct; 20(10):1321-41. PubMed ID: 20670208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of β-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria.
    Tang SS; Apisarnthanarak A; Hsu LY
    Adv Drug Deliv Rev; 2014 Nov; 78():3-13. PubMed ID: 25134490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.